Aurinia Pharmaceuticals (NASDAQ: AUPH) grows profit and cash in Q2 2026
Aurinia Pharmaceuticals Inc. delivered higher profitability for the quarter ended June 30, 2026, driven by growth in LUPKYNIS. Net product sales were $79.4 million in the quarter and $153.0 million year‑to‑date, and diluted earnings per share reached $0.28 for the quarter.
Net income and operating cash flow both increased versus 2025, with cash flows from operating activities of $85.1 million for the first six months. Cash, cash equivalents, restricted cash and investments rose to $443.1 million, even after repurchasing 5.0 million common shares for $74.9 million.
Aurinia advanced its autoimmune pipeline by initiating PRESERVE, a Phase 4 study combining LUPKYNIS with several biologics in lupus nephritis, and by progressing aritinercept in four indications. It also completed an asset acquisition of Kezar Life Sciences, adding cash, in‑process R&D and a contingent value right structure.
Positive
- None.
Negative
- None.
Filing Explained
At June 30, 2026, 4.3 million potential shares entered diluted EPS, while 5.0 million repurchased shares had been cancelled.
This unaudited Form 10-Q reports results for the quarter ended
The filing treats stock options, PSUs, RSUs and ESPP shares as potential common shares when their effect is dilutive. For the six months ended
During the six-month period, the company repurchased 5.0 million common shares for
The completed Kezar acquisition also left a recorded
Key Figures
LUPKYNIS net product sales H1 2026: $153.0 million
Cash and investments: $443.1 million
Operating cash flow H1 2026: $85.1 million
+4 more
7 metrics
LUPKYNIS net product sales H1 2026
$153.0 million
Net product sales for the six months ended June 30, 2026
Cash and investments
$443.1 million
Cash, cash equivalents, restricted cash and investments as of June 30, 2026
Operating cash flow H1 2026
$85.1 million
Cash flows from operating activities for the six months ended June 30, 2026
Diluted EPS Q2 2026
$0.28
Diluted earnings per share for the three months ended June 30, 2026
Shares repurchased H1 2026
5.0 million shares
Common shares repurchased for $74.9 million in the six months ended June 30, 2026
Kezar acquisition consideration
$55,488 (in thousands)
Total purchase consideration for Kezar Life Sciences as of May 11, 2026
CVR liability recorded
$3.7 million
Contingent value right liability related to Kezar Net Cash Excess as of June 30, 2026
Key Terms
contingent value right, Monoplant, lupus nephritis, Phase 4, +1 more
5 terms
contingent value right financial
"plus one non-transferable contingent value right (“CVR”), which represents the right to receive"
A contingent value right is a special security that gives its holder the right to receive one or more future payments only if specified events happen, such as a product reaching a sales target or getting regulatory approval. It matters to investors because it offers potential extra payout tied to uncertain outcomes—like a bet that a project will succeed—so it can add upside to a deal while also carrying extra risk and valuation uncertainty.
Monoplant technical
"a dedicated manufacturing facility at Lonza Ltd. (the “Monoplant”), Aurinia’s contract manufacturing partner"
lupus nephritis medical
"LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis"
Lupus nephritis is a condition in which a person’s immune system attacks the kidneys, causing inflammation and damage to the organs’ filtering function and leading to blood or protein in the urine and, in severe cases, kidney failure. For investors, it defines a specific, medically serious patient group and treatment need: success or failure of therapies, clinical trials, regulatory approvals, and pricing decisions for drugs aimed at this condition can meaningfully change a biotech or pharma company’s revenue prospects — like fixing a costly, central leak in a building that determines the value of the whole property.
Phase 4 medical
"initiated PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS"
Phase 4 is the stage after a drug or vaccine has been approved and is sold to the public, where regulators and companies keep watching how it performs in the real world to detect rare side effects, long‑term effects, or differences in effectiveness across different groups. Think of it as ongoing quality control for a product already on shelves; results can prompt label changes, safety warnings, sales impacts or recalls, all of which matter to investors evaluating risk and future revenue.
share repurchase program financial
"Board had approved a share repurchase program of up to $150 million of the Company’s common shares"
A share repurchase program is when a company buys back its own shares from the marketplace. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's prospects. For investors, it often suggests that the company believes its stock is undervalued or that it has extra cash to return to shareholders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
See more from StockTitan in Google Search and AI answers.
Adds StockTitan as a preferred source · opens Google
FAQ
How did Aurinia Pharmaceuticals (AUPH) perform financially in Q2 2026?
Aurinia reported stronger results in Q2 2026, with total revenue of 83,220 (in thousands) and net income of 37,414 (in thousands). Diluted earnings per share were $0.28, compared with $0.16 a year earlier, reflecting improved profitability.
What were LUPKYNIS net product sales for AUPH in Q2 and the first half of 2026?
Net product sales of LUPKYNIS were $79.4 million in Q2 2026 and $153.0 million for the first six months. These figures were up 19% and 21%, respectively, from the same periods in 2025, driven mainly by increased cartons sold to specialty pharmacies.
What is Aurinia Pharmaceuticals' (AUPH) cash position as of June 30, 2026?
As of June 30, 2026, Aurinia held $443.1 million in cash, cash equivalents, restricted cash and investments. This compares with $398.0 million at December 31, 2025, reflecting strong operating cash flow and cash acquired in the Kezar Life Sciences transaction.
How strong were Aurinia Pharmaceuticals' (AUPH) operating cash flows in H1 2026?
For the six months ended June 30, 2026, Aurinia generated $85.1 million of cash flows from operating activities. This represented an 87% increase from $45.5 million in the prior‑year period, supported by higher profitability and working capital movements.
What are the key terms of Aurinia's acquisition of Kezar Life Sciences?
On May 11, 2026, Aurinia acquired Kezar Life Sciences for $6.955 in cash per share plus a non‑transferable contingent value right. Total purchase consideration was $55,488 (in thousands), including $51,599 (in thousands) cash, $3,700 (in thousands) CVR consideration and $189 (in thousands) transaction costs.
How much stock did Aurinia Pharmaceuticals (AUPH) repurchase under its plan in H1 2026?
In the six months ended June 30, 2026, Aurinia repurchased 5.0 million common shares for $74.9 million, including commissions and excise tax. Since the program began in February 2024, cumulative repurchases total 23.3 million shares for $213.4 million, excluding commissions and excise tax.
What pipeline and clinical developments did Aurinia Pharmaceuticals (AUPH) report in 2026?
Aurinia initiated PRESERVE, a Phase 4 study combining LUPKYNIS with belimumab, obinutuzumab or anifrolumab in lupus nephritis, targeting about 150 U.S. patients. The company also advanced aritinercept, a dual BAFF/APRIL inhibitor, into clinical development across four potential autoimmune indications.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_____________________________________________
FORM 10-Q
_____________________________________________
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the quarterly period ended June 30, 2026
OR
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the transition period from_____________ to ________________
Commission file number: 001-36421
__________________________________________
(Exact Name of Registrant as Specified in its Charter)
__________________________________________
Alberta, | |||||
| (State or other jurisdiction of incorporation or organization) | |||||
| (Address of principal executive offices) | (I.R.S. Employer Identification Number) | ||||
Registrant’s telephone number, including area code
_____________________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| x | Accelerated filer | ☐ | ||||||||||||
| Non-accelerated filer | ☐ | Smaller reporting company | ||||||||||||
| Emerging growth company | ||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
Indicate the number of shares outstanding of each of the registrant's classes of common shares, as of the latest predictable date. As of August 5, 2026, the registrant had 133,051,168 of common shares outstanding.
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of exchange on which registered | ||||||
Table of Contents
| Page | ||||||||||||||
PART I. | FINANCIAL INFORMATION | 1 | ||||||||||||
Item 1. | Financial Statements | 1 | ||||||||||||
Condensed Consolidated Balance Sheets as of June 30, 2026 (Unaudited) and December 31, 2025 | 1 | |||||||||||||
Condensed Consolidated Statements of Operations and Comprehensive Income for the Three and Six Months Ended June 30, 2026 and 2025 (Unaudited) | 2 | |||||||||||||
Condensed Consolidated Statements of Shareholders’ Equity for the Three and Six Months Ended June 30, 2026 and 2025 (Unaudited) | 3 | |||||||||||||
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2026 and 2025 (Unaudited) | 5 | |||||||||||||
Notes to Condensed Consolidated Financial Statements (Unaudited) | 7 | |||||||||||||
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 16 | ||||||||||||
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 21 | ||||||||||||
Item 4. | Controls and Procedures | 21 | ||||||||||||
PART II. | OTHER INFORMATION | 22 | ||||||||||||
Item 1. | Legal Proceedings | 22 | ||||||||||||
Item 1A. | Risk Factors | 22 | ||||||||||||
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 22 | ||||||||||||
Item 3. | Defaults Upon Senior Securities | 22 | ||||||||||||
Item 4. | Mine Safety Disclosures | 22 | ||||||||||||
Item 5. | Other Information | 22 | ||||||||||||
Item 6. | Exhibits | 23 | ||||||||||||
Signatures | 24 | |||||||||||||
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements.
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
| June 30, 2026 | December 31, 2025 | |||||||||||||
(Unaudited) | ||||||||||||||
| ASSETS | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash, cash equivalents and restricted cash | $ | $ | ||||||||||||
| Short-term investments | ||||||||||||||
| Accounts receivable, net | ||||||||||||||
| Inventory | ||||||||||||||
| Prepaid expenses and deposits | ||||||||||||||
| Other current assets | ||||||||||||||
| Total current assets | ||||||||||||||
Deferred tax assets, net | ||||||||||||||
| Finance right-of-use lease assets | ||||||||||||||
| Intangible assets, net | ||||||||||||||
| Operating right-of-use lease assets | ||||||||||||||
| Property and equipment, net | ||||||||||||||
| Other noncurrent assets | ||||||||||||||
| Total assets | $ | $ | ||||||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Accounts payable | $ | $ | ||||||||||||
| Accrued expenses | ||||||||||||||
| Finance lease liabilities, current portion | ||||||||||||||
| Deferred revenue | ||||||||||||||
| Operating lease liabilities, current portion | ||||||||||||||
| Other current liabilities | ||||||||||||||
| Total current liabilities | ||||||||||||||
| Finance lease liabilities, less current portion | ||||||||||||||
| Deferred tax benefits | ||||||||||||||
| Deferred revenue, less current portion | ||||||||||||||
| Operating lease liabilities, less current portion | ||||||||||||||
| Other noncurrent liabilities | ||||||||||||||
| Total liabilities | ||||||||||||||
Commitments and contingencies (Note 5) | ||||||||||||||
| Shareholders' equity | ||||||||||||||
Common shares — | ||||||||||||||
| Additional paid-in capital | ||||||||||||||
| Accumulated other comprehensive loss | ( | ( | ||||||||||||
| Accumulated deficit | ( | ( | ||||||||||||
| Total shareholders' equity | ||||||||||||||
| Total liabilities and shareholders' equity | $ | $ | ||||||||||||
See accompanying notes.
1
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(Unaudited)
(in thousands, except per share data)
Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Revenue | ||||||||||||||||||||||||||
Net product sales | $ | $ | $ | $ | ||||||||||||||||||||||
License, collaboration and royalty revenue | ||||||||||||||||||||||||||
Total revenue | ||||||||||||||||||||||||||
| Operating expenses | ||||||||||||||||||||||||||
| Cost of revenue | ||||||||||||||||||||||||||
| Selling, general and administrative | ||||||||||||||||||||||||||
| Research and development | ||||||||||||||||||||||||||
| Restructuring | ||||||||||||||||||||||||||
| Other (income) expense, net | ( | ( | ||||||||||||||||||||||||
| Total operating expenses | ||||||||||||||||||||||||||
| Income from operations | ||||||||||||||||||||||||||
| Interest income | ||||||||||||||||||||||||||
| Interest expense | ( | ( | ( | ( | ||||||||||||||||||||||
| Net income before income taxes | ||||||||||||||||||||||||||
| Income tax expense | ||||||||||||||||||||||||||
| Net income | $ | $ | $ | $ | ||||||||||||||||||||||
| Other comprehensive income: | ||||||||||||||||||||||||||
Unrealized loss on available-for-sale securities | ( | ( | ( | ( | ||||||||||||||||||||||
| Comprehensive income | $ | $ | $ | $ | ||||||||||||||||||||||
| Earnings per share | ||||||||||||||||||||||||||
| Basic | $ | $ | $ | $ | ||||||||||||||||||||||
| Diluted | $ | $ | $ | $ | ||||||||||||||||||||||
| Shares used in computing earnings per share | ||||||||||||||||||||||||||
| Basic | ||||||||||||||||||||||||||
| Diluted | ||||||||||||||||||||||||||
See accompanying notes.
2
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(Unaudited)
(in thousands)
| Common Shares | ||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Additional paid-in capital | Accumulated Other Comprehensive Loss | Accumulated Deficit | Total Shareholders' Equity | |||||||||||||||||||||||||||||||||
Balance at December 31, 2025 | $ | $ | $ | ( | $ | ( | $ | |||||||||||||||||||||||||||||||
Purchases of common shares under Share Repurchase Plan | ( | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||
Issuance of common shares for equity awards | ( | — | — | |||||||||||||||||||||||||||||||||||
Tax withholding related to net settlement of equity awards | ( | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||
Share-based compensation | — | — | ( | — | — | ( | ||||||||||||||||||||||||||||||||
Unrealized loss on available-for-sale securities, net | — | — | — | ( | — | ( | ||||||||||||||||||||||||||||||||
Net income | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Balance at March 31, 2026 | $ | $ | $ | ( | $ | ( | $ | |||||||||||||||||||||||||||||||
| Purchases of common shares under Share Repurchase Plan | ( | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||
| Issuance of common shares for equity awards | ( | — | — | |||||||||||||||||||||||||||||||||||
| Issuance of common shares under ESPP | ( | — | — | |||||||||||||||||||||||||||||||||||
| Tax withholding related to net settlement of equity awards | ( | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||
| Share-based compensation | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Unrealized loss on available-for-sale securities, net | — | — | — | ( | — | ( | ||||||||||||||||||||||||||||||||
| Net income | — | — | — | |||||||||||||||||||||||||||||||||||
| Balance at June 30, 2026 | $ | $ | $ | ( | $ | ( | $ | |||||||||||||||||||||||||||||||
3
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(Unaudited)
(in thousands)
| Common Shares | ||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Additional paid-in capital | Accumulated Other Comprehensive Loss | Accumulated Deficit | Total Shareholders' Equity | |||||||||||||||||||||||||||||||||
Balance at December 31, 2024 | $ | $ | $ | ( | $ | ( | $ | |||||||||||||||||||||||||||||||
Purchases of common shares under Share Repurchase Plan | ( | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||
Issuance of common shares for equity awards | ( | — | — | |||||||||||||||||||||||||||||||||||
Share-based compensation | — | — | ( | — | — | ( | ||||||||||||||||||||||||||||||||
Unrealized loss on available-for-sale securities | — | — | — | ( | — | ( | ||||||||||||||||||||||||||||||||
Net income | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Balance at March 31, 2025 | $ | $ | $ | ( | $ | ( | $ | |||||||||||||||||||||||||||||||
Purchases of common shares under Share Repurchase Plan | ( | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||
| Issuance of common shares for equity awards | ( | — | — | |||||||||||||||||||||||||||||||||||
Issuance of common shares under ESPP | ( | — | — | |||||||||||||||||||||||||||||||||||
| Share-based compensation | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Unrealized loss on available-for-sale securities | — | — | — | ( | — | ( | ||||||||||||||||||||||||||||||||
Net income | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Balance at June 30, 2025 | $ | $ | $ | ( | $ | ( | $ | |||||||||||||||||||||||||||||||
4
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(in thousands)
| Six Months Ended June 30, | ||||||||||||||
| 2026 | 2025 | |||||||||||||
Cash flows from operating activities: | ||||||||||||||
| Net income | $ | $ | ||||||||||||
| Adjustments to reconcile net income to cash flows from operating activities: | ||||||||||||||
| Deferred income tax | ||||||||||||||
| Share-based compensation | ||||||||||||||
| Amortization and depreciation | ||||||||||||||
| Foreign exchange (gain) loss on revaluation of Monoplant finance lease liability | ( | |||||||||||||
| Net amortization of premiums and discounts on investments | ( | ( | ||||||||||||
| Other, net | ( | |||||||||||||
| Net changes in operating assets and liabilities: | ||||||||||||||
| Accounts receivable, net | ( | |||||||||||||
| Inventory | ( | |||||||||||||
| Prepaid expenses and other current assets | ( | |||||||||||||
| Other noncurrent operating assets | ||||||||||||||
| Accounts payable | ( | ( | ||||||||||||
| Accrued expenses and other liabilities | ( | ( | ||||||||||||
| Deferred revenue | ||||||||||||||
| Operating lease liabilities | ( | ( | ||||||||||||
| Cash flows from operating activities | ||||||||||||||
| Cash flows from investing activities: | ||||||||||||||
| Proceeds from the sale and maturities of investments | ||||||||||||||
| Purchases of investments | ( | ( | ||||||||||||
| Net cash and cash equivalents acquired in acquisition of Kezar | ||||||||||||||
| Purchases of property, equipment and intangible assets | ( | ( | ||||||||||||
| Cash flows from investing activities | ||||||||||||||
| Cash flows from financing activities: | ||||||||||||||
| Purchase of common shares under Share Repurchase Plan | ( | ( | ||||||||||||
| Payments of principal portion of Monoplant finance lease liability | ( | ( | ||||||||||||
| Proceeds from issuance of common shares for equity awards | ||||||||||||||
Proceeds from issuance of common shares under ESPP | ||||||||||||||
| Tax withholding payments related to net settlements of equity awards | ( | ( | ||||||||||||
| Cash flows from financing activities | ( | ( | ||||||||||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | ( | |||||||||||||
| Cash, cash equivalents and restricted cash, beginning of the period | ||||||||||||||
| Cash, cash equivalents and restricted cash, end of the period | $ | $ | ||||||||||||
| Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets: | ||||||||||||||
Cash and cash equivalents | $ | $ | ||||||||||||
| Restricted cash | ||||||||||||||
Total cash, cash equivalents and restricted cash | $ | $ | ||||||||||||
5
| Supplemental cash flow information: | ||||||||||||||
| Cash paid for taxes | $ | $ | ||||||||||||
| Non-cash investing and financing activities: | ||||||||||||||
| Accrual of contingent value rights liability in acquisition of Kezar | $ | $ | ||||||||||||
| Accrual of tax withholding payments related to exercise of stock options | $ | $ | ||||||||||||
See accompanying notes.
6
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1.Organization and Description of Business
Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (“BAFF”) and a proliferation-inducing ligand (“APRIL”) for the potential treatment of autoimmune diseases.
2.Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation, Principles of Consolidation and Use of Estimates
The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and disclosures required by U.S. GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
The accompanying condensed consolidated financial statements include the accounts of Aurinia Pharmaceuticals Inc. and its wholly owned subsidiaries, including Kezar Life Sciences, Inc.’s financial results subsequent to the acquisition closing date of May 11, 2026. All intercompany balances and transactions have been eliminated in consolidation. The results of operations for the three and six months ended June 30, 2026 are not necessarily indicative of the results to be expected for the full year or any other future periods.
Summary of Significant Accounting Policies and Recent Accounting Pronouncements
The Company’s significant accounting policies and recent accounting pronouncements have not materially changed from those previously described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 except as noted below.
Acquisitions
The Company evaluates business acquisitions to determine whether a transaction should be accounted for as a business combination or an asset acquisition under ASC Topic 805, Business Combinations (“ASC 805”). The Company considers whether substantially all of the fair value of the gross assets acquired is concentrated in a single asset or group of similar assets. If not, the Company evaluates whether the acquired assets include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs.
Asset acquisitions are accounted for using the cost accumulation method, under which the purchase price, including certain transaction costs, is allocated to the assets acquired on a relative fair value basis. Acquired in-process research and development pursuant to an asset acquisition that has no alternative future use is expensed immediately as a component of in-process research and development expense in the condensed consolidated statements of operations.
Contingent payments are evaluated to determine whether they are instruments within the scope of ASC Topic 815, Derivatives and Hedging (“ASC 815”). If so, contingent payments are recorded at fair value on the acquisition date and remeasured to fair value at each reporting date. These changes in fair value are recognized in the condensed consolidated statements of operations. If not, contingent payments are recognized when the amounts are probable and estimable under ASC Topic 450, Contingencies (“ASC 450”).
ASC 740-10-25-49, Acquired Temporary Differences in Certain Purchase Transactions That Are Not Accounted for as Business Combinations (“ASC 740”), provides guidance that addresses the accounting when an asset is acquired outside of a business combination and the tax basis of the asset differs from the amount paid. Any deferred tax assets acquired in an asset acquisition that are realizable are included in the net assets acquired.
7
Under ASC 740, any purchase of future tax benefits from a third party shall be recorded as a deferred credit and shall not result in immediate income statement recognition. The deferred credit shall not be classified as part of deferred tax liabilities or as an offset to deferred tax assets. Therefore, on the acquisition date, the Company recorded $23.1 million of deferred tax assets in noncurrent assets and $23.1 million of deferred tax benefits in noncurrent liabilities on the condensed consolidated balance sheet. The deferred tax benefits will be recognized when the Company has future U.S. taxable income and will reduce income tax expense.
Cash paid related to acquisitions is recorded in cash flows from investing activities net of cash acquired.
Accounting Pronouncements Recently Adopted
In September 2025, the FASB issued ASU 2025-07, Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract (“ASU 2025-07”). ASU 2025-07 expands the scope exception in ASC Topic 815 for certain contracts not traded on an exchange whose settlement is based on the operations or activities of one of the parties to the contract. ASU 2025-07 also clarifies ASC Topic 606 for share-based payments received from a customer in a revenue contract. The Company elected to early adopt ASU 2025-07 on a prospective basis during the three months ended June 30, 2026. The new scope exception in ASC Topic 815 was applied to the evaluation of contingent payments related to the acquisition of Kezar. See Note 8 for the effect on the condensed consolidated financial statements. The new accounting standard related to share-based payments received from a customer in a revenue contract had no impact on our condensed consolidated financial statements.
3.Earnings Per Share
Basic earnings per share is calculated by dividing net income by the weighted-average number of common shares outstanding without consideration of potential common shares. Diluted earnings per share is calculated by dividing net income by the weighted-average number of common shares outstanding plus potential common shares. Stock options, performance stock units (“PSUs”), restricted stock units (“RSUs”) and shares issuable under the Company’s Employee Stock Purchase Plan (“ESPP”) are considered potential common shares and are included in the calculation of diluted earnings per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted earnings per share when their effect is anti-dilutive.
For the three months ended June 30, 2026, there were 3.5 million potential dilutive common shares that were included in the calculation of diluted earnings per share, which consists of: (i) 2.6 million stock options; (ii) 0.6 million PSUs; and (iii) 0.3 million RSUs. For the six months ended June 30, 2026, there were 4.3 million potential dilutive common shares that were included in the calculation of diluted earnings per share, which consists of: (i) 2.6 million stock options; (ii) 0.9 million RSUs; and (iii) 0.8 million PSUs. For each of the three and six months ended June 30, 2026, there were 2.7
For the three months ended June 30, 2025, there were 2.6 million potential dilutive common shares that were included in the calculation of diluted earnings per share, which consists of: (i) 0.5 million stock options; (ii) 0.5 million PSUs; and (iii) 1.6 million RSUs. For the six months ended June 30, 2025, there were 3.3 million potential dilutive common shares that were included in the calculation of diluted earnings per share, which consists of: (i) 0.5 million stock options; (ii) 2.2 million RSUs; and (iii) 0.6 million PSUs. For each of the three and six months ended June 30, 2025, there were 7.5
8
4. Balance Sheet Details
Fair Value Measurement
The following table summarizes the financial assets measured at fair value on a recurring basis (in thousands):
| June 30, 2026 | ||||||||||||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||||||
Cash, cash equivalents and restricted cash | $ | $ | $ | $ | ||||||||||||||||||||||
| U.S. treasury bills | ||||||||||||||||||||||||||
| U.S. treasury bonds | ||||||||||||||||||||||||||
| Commercial paper | ||||||||||||||||||||||||||
Total | $ | $ | $ | $ | ||||||||||||||||||||||
| December 31, 2025 | ||||||||||||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||||||
Cash, cash equivalents and restricted cash | $ | $ | $ | $ | ||||||||||||||||||||||
U.S. treasury bills | ||||||||||||||||||||||||||
| U.S. treasury bonds | ||||||||||||||||||||||||||
| Commercial paper | ||||||||||||||||||||||||||
Total | $ | $ | $ | $ | ||||||||||||||||||||||
The fair value of the Company’s investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications.
The carrying amount and related unrealized gains (losses) by type of investment consisted of the following (in thousands):
| June 30, 2026 | ||||||||||||||||||||||||||
| Amortized Cost | Unrealized Gains | Unrealized Losses | Estimated Fair Value | |||||||||||||||||||||||
Cash, cash equivalents and restricted cash | $ | $ | $ | $ | ||||||||||||||||||||||
U.S. treasury bills | ( | |||||||||||||||||||||||||
U.S. treasury bonds | ( | |||||||||||||||||||||||||
| Commercial paper | ||||||||||||||||||||||||||
Total cash, cash equivalents, restricted cash and short-term investments | $ | $ | $ | ( | $ | |||||||||||||||||||||
| December 31, 2025 | ||||||||||||||||||||||||||
| Amortized Cost | Unrealized Gains | Unrealized Losses | Estimated Fair Value | |||||||||||||||||||||||
Cash, cash equivalents and restricted cash | $ | $ | $ | $ | ||||||||||||||||||||||
U.S. treasury bills | ||||||||||||||||||||||||||
U.S. treasury bonds | ||||||||||||||||||||||||||
| Commercial paper | ||||||||||||||||||||||||||
| Total cash, cash equivalents, restricted cash and short-term investments | $ | $ | $ | $ | ||||||||||||||||||||||
As of June 30, 2026 and December 31, 2025, accrued interest receivable from investments was $1.0 million and $0.7 million, respectively, which was included in other current assets on the condensed consolidated balance sheets. As of June 30, 2026, short-term investments mature at various dates through May 2027. As of June 30, 2026 and December 31, 2025, no allowance for credit losses was recorded.
9
Inventory
Inventory consisted of the following (in thousands):
| June 30, 2026 | December 31, 2025 | |||||||||||||
| Raw materials | $ | $ | ||||||||||||
| Work in process | ||||||||||||||
Finished goods | ||||||||||||||
Total inventory | $ | $ | ||||||||||||
Prepaid Expenses and Deposits
Prepaid expenses and deposits consisted of the following (in thousands):
| June 30, 2026 | December 31, 2025 | |||||||||||||
Prepaid manufacturing and other deposits | $ | $ | ||||||||||||
Other prepaid expenses | ||||||||||||||
Total prepaid expenses and deposits | $ | $ | ||||||||||||
Intangible Assets, Net
Intangible assets, net consisted of the following (in thousands):
| June 30, 2026 | ||||||||||||||||||||
| Gross Carrying Value | Accumulated Amortization | Net Carrying Amount | ||||||||||||||||||
| Acquired intellectual property and reacquired right | $ | $ | ( | $ | ||||||||||||||||
| Patents | ( | |||||||||||||||||||
| Internal-use software implementation costs | ( | |||||||||||||||||||
Total intangible assets, net | $ | $ | ( | $ | ||||||||||||||||
| December 31, 2025 | ||||||||||||||||||||
| Gross Carrying Value | Accumulated Amortization | Net Carrying Amount | ||||||||||||||||||
| Acquired intellectual property and reacquired right | $ | $ | ( | $ | ||||||||||||||||
| Patents | ( | |||||||||||||||||||
| Internal-use software implementation costs | ( | |||||||||||||||||||
Total intangible assets, net | $ | $ | ( | $ | ||||||||||||||||
For each of the three months ended June 30, 2026 and 2025, the Company recorded amortization expense of $0.2 0.4
Property and Equipment, Net
Property and equipment, net consisted of the following (in thousands):
| June 30, 2026 | December 31, 2025 | |||||||||||||
| Leasehold improvements | $ | $ | ||||||||||||
Furniture | ||||||||||||||
Office equipment | ||||||||||||||
Computer equipment | ||||||||||||||
Total gross property and equipment | ||||||||||||||
| Less accumulated depreciation | ( | ( | ||||||||||||
| Property and equipment, net | $ | $ | ||||||||||||
10
Accrued Expenses
Accrued expenses consisted of the following (in thousands):
| June 30, 2026 | December 31, 2025 | |||||||||||||
Accrued sales rebates and fees | $ | $ | ||||||||||||
Accrued payroll and related expenses | ||||||||||||||
Accrued research and development expenses | ||||||||||||||
| Accrued sales and marketing expenses | ||||||||||||||
| Accrued corporate and excise taxes | ||||||||||||||
Accrued other expenses | ||||||||||||||
Total accrued expenses | $ | $ | ||||||||||||
5.Commitments and Contingencies
Lease Commitments
Finance Lease
Monoplant
In December 2020, the Company entered into a manufacturing services agreement with Lonza Ltd., Aurinia’s contract manufacturing partner for voclosporin, for the construction of a dedicated manufacturing facility for voclosporin (the “Monoplant”). The construction of the Monoplant began in January 2021 and manufacturing of voclosporin began in late June 2023. The Monoplant is equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacturing of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand. The Company completed a capital expenditure payment program for the Monoplant totaling $23.7 million, which included: (i) a $11.8 million payment in February 2021, which was treated as an upfront lease payment and recorded under other noncurrent assets on the consolidated balance sheets; and (ii) a $11.9 million payment when the facility fulfilled the required operational qualifications, which occurred in late June 2023. The Company has the exclusive right to use the Monoplant through March 31, 2030 by paying a quarterly fixed facility fee of 3.6 million Swiss Francs.
The Monoplant arrangement was determined to be an embedded lease and is accounted for as a finance lease under ASC 842. The lease term is based on the non-cancellable period for which a lessee has the right to use an underlying asset (the “Monoplant Lease”). The Company determined that the Monoplant Lease commencement occurred at the point when the FDA manufacturing validation process began, which occurred on June 26, 2023. At lease inception, the Company recorded a finance right-of-use (“ROU”) lease asset and a corresponding lease liability. As of June 30, 2026, the Monoplant Lease finance ROU lease asset and corresponding lease liability balance were $65.2 million and $60.4 million, respectively.
Operating Lease
Rockville, Maryland
In March 2020, the Company entered into a lease agreement for 30,531 square feet of office space in Rockville, Maryland (the “Rockville Lease”). The Rockville Lease commenced on March 12, 2020 and expires on August 31, 2031. Pursuant to the Rockville Lease, the Company has an option to either terminate the lease early on August 31, 2028, subject to an early termination fee of $1.4 million, or extend the lease for two 5-year periods at the end of the initial 11-year term. The Company has determined that it is reasonably certain that it will exercise the early termination option, which will result in a reduction of approximately $2.3 million of future lease payments net of the early termination fee. Nevertheless, the Company is exploring sublease options for potential savings in excess of the early termination option. The Rockville Lease requires the Company to pay certain taxes, insurance and operating costs relating to the leased premises (“Lease Operating Costs”); however, such costs are not material to the Company’s financial position.
11
Future minimum lease payments, excluding Lease Operating Costs, as of June 30, 2026 consisted of the following (in thousands):
| Finance Lease Payments | Operating Lease Payments | |||||||||||||
| Remainder of 2026 | $ | $ | ||||||||||||
| 2027 | ||||||||||||||
| 2028 | ||||||||||||||
| 2029 | ||||||||||||||
| 2030 | ||||||||||||||
Total lease payments | ||||||||||||||
Less: imputed interest | ( | ( | ||||||||||||
Total | $ | $ | ||||||||||||
For each of the three months ended June 30, 2026 and 2025, finance lease expense related to the amortization of finance ROU lease assets was $4.4 8.7 million and $8.8 million, respectively. For the three months ended June 30, 2026 and 2025, interest expense on finance lease liabilities was $0.9 million and $1.1 million, respectively. For the six months ended June 30, 2026 and 2025, interest expense on finance lease liabilities was $2.0 million and $2.2 million, respectively.
For the six months ended June 30, 2026 and 2025, cash paid for amounts included in the measurement of finance lease liabilities classified in cash flows from financing activities was $7.1 million and $6.2 million, respectively. For each of the six months ended June 30, 2026 and 2025, cash paid for amounts included in the measurement of finance lease liabilities classified in cash flows from operating activities was $2.3
Manufacturing Commitments
The Company’s manufacturing commitments have not changed in any material manner from those previously described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
Contingencies
From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation other than as described in Item 1 of Part II Legal Proceedings.
6.Other Noncurrent Liabilities
In March 2012, the Company entered into arrangements with certain former executive officers, whereby the Company is required to make payments to such former officers based on net revenues of voclosporin for a certain period of time. As of June 30, 2026 and December 31, 2025, the Company recorded other noncurrent liabilities of $0.9 million and $6.7 million, respectively. During the three months ended June 30, 2026, the Company made a one-time payment to fully settle all future obligations under one former officer’s arrangement.
7.License and Collaboration Agreements
In December 2020, the Company entered into a collaboration and licensing agreement with Otsuka to develop and commercialize oral voclosporin in Japan, the European Union (the “E.U.”), the United Kingdom (“U.K.”), Switzerland, Russia, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the “Otsuka Territories”) in exchange for: (i) a $50 million upfront cash payment; (ii) regulatory and commercial milestone payments; and (iii) royalties ranging from 10 % to 20 % on net sales in the Otsuka Territories.
In August 2022, the Company entered into a commercial supply agreement with Otsuka to: (i) supply LUPKYNIS inventory to Otsuka at cost plus a margin; and (ii) provide manufacturing and other services, including sharing the capacity of the Monoplant. For the three months ended June 30, 2026 and 2025, the Company recognized $3.8 million and $3.4 million, respectively, of collaboration revenue from manufacturing and other services, which includes sharing capacity of the Monoplant. For the six months ended June 30, 2026 and 2025, the Company recognized $8.0 million and $5.9 million, respectively, of collaboration revenue from manufacturing and other services, which includes sharing capacity of the Monoplant.
12
8.Acquisition
On May 11, 2026, Aurinia completed its acquisition of Kezar Life Sciences, Inc. (“Kezar”) for $6.955 in cash per share of Kezar common stock, plus one non-transferable contingent value right (“CVR”), which represents the right to receive: (i) potential payments relating to the ongoing clinical development or disposition of zetomipzomib; (ii) certain proceeds relating to Kezar’s collaboration with Everest Medicines and Kezar’s sale of its Sec61‑based discovery and development program to Enodia Therapeutics; and (iii) 100 % of Kezar’s closing net cash in excess of $50 million, net of certain post-closing CVR-related expenses (“Net Cash Excess”).
The Company concluded that the CVRs are contingent liabilities under the scope of ASC Topic 450 and will be recognized when the amounts are probable and estimable. As of June 30, 2026, the Company recorded a CVR liability of $3.7 million related to the Net Cash Excess within other current liabilities in the condensed consolidated balance sheet.
As of May 11, 2026, the total purchase consideration for Kezar was as follows (in thousands):
| Cash consideration paid at closing | $ | |||||||
| CVR consideration payable | ||||||||
| Transaction costs | ||||||||
| Total purchase consideration | $ | |||||||
The following table shows the allocation of the purchase consideration based on the relative fair values of assets acquired and liabilities assumed by the Company on May 11, 2026 (in thousands):
| Cash and cash equivalents | $ | |||||||
| Deferred tax assets | ||||||||
| Interest receivable | ||||||||
| Deferred tax benefits | ( | |||||||
| Accounts payable and accrued expenses | ( | |||||||
| Net assets acquired | ||||||||
| Reconciliation of net assets acquired to total purchase consideration | ||||||||
| Acquired in-process research and development | ||||||||
| Total purchase consideration | $ | |||||||
9.Shareholders’ Equity
In February 2024, the Company announced that the Board had approved a share repurchase program of up to $150 million of the Company’s common shares (the “Share Repurchase Plan”). In July 2025, the Company announced that the Board approved an increase to the previously announced Share Repurchase Plan of an additional $150 million of the Company’s common shares.
The timing and amount of future repurchase transactions will be determined by the Company based on its evaluation of market conditions, share price, legal requirements, including applicable blackout period restrictions, and other factors. The Company has entered into a Rule 10b5-1 stock repurchase plan for the purpose of establishing a trading plan to purchase the Company’s common shares in a manner intended to satisfy the affirmative defense of Rule 10b5-1(c)(1) under the Securities Exchange Act of 1934, as amended and in accordance with applicable Canadian laws.
13
For the three months ended June 30, 2026 and 2025, the Company repurchased 2.5 million and 5.4 million of its common shares for $38.1 million and $43.4 million, respectively, including commissions and excise tax. For the six months ended June 30, 2026 and 2025, the Company repurchased 5.0 million and 11.2 million of its common shares for $74.9 million and $90.8 million, respectively, including commissions and excise tax. The cost of repurchased shares is recorded as a reduction in common shares. Under Alberta law, the common shares were cancelled and not reissued.
Purchases under the Share Repurchase Plan, which to date have totaled 23.3 million of the Company’s common shares for $213.4 million, excluding commissions and excise tax, began on February 21, 2024.
10.Equity Incentive Plans
Stock Options
The activity related to stock options during the six months ended June 30, 2026 consisted of the following:
| June 30, 2026 | ||||||||||||||
| Number of shares (in thousands) | Weighted-Average Exercise Price | |||||||||||||
Outstanding at December 31, 2025 | $ | |||||||||||||
| Granted | ||||||||||||||
Exercised/released | ( | |||||||||||||
Cancelled/forfeited | ( | |||||||||||||
| Outstanding at June 30, 2026 | $ | |||||||||||||
The following weighted-average assumptions were used to estimate the fair value of the options granted during the six months ended June 30, 2026 and 2025:
| Six Months Ended June 30, | ||||||||||||||
| 2026 | 2025 | |||||||||||||
| Expected volatility | % | % | ||||||||||||
| Risk-free interest rate | % | % | ||||||||||||
| Expected term (in years) | ||||||||||||||
| Expected dividend yield | % | |||||||||||||
| Fair value per common share option | $ | $ | ||||||||||||
Performance Stock Units and Restricted Stock Units
During the six months ended June 30, 2026 and 2025, the Company granted PSUs that vest in 4 four one year 2 tranches at the 3 - and 5 -year anniversary date of the grant upon the Company’s common shares achieving specified target prices that represent significant increases from the share price on the date of grant before the respective vesting date. The Company estimated the fair value of each PSU with a market and service condition on the date of grant by using a Monte Carlo simulation (lattice model).
Beginning in 2026, RSUs are no longer being granted. RSUs granted prior to 2026 vest in 3 equal annual installments on the first, second and third anniversary of the grant date. The fair value of RSUs is based on the market price of the Company’s common shares on the date prior to the grant.
14
The activity related to PSUs and RSUs for the six months ended June 30, 2026 consisted of the following:
| June 30, 2026 | ||||||||||||||
| Number of shares (in thousands) | Weighted-average fair value $ | |||||||||||||
Unvested balance, December 31, 2025 | $ | |||||||||||||
| Granted | ||||||||||||||
| Vested | ( | |||||||||||||
Cancelled/forfeited | ( | |||||||||||||
| Unvested balance, June 30, 2026 | $ | |||||||||||||
Share-based Compensation Expense
The classification of share-based compensation expense consisted of the following (in thousands):
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||||||||||||
| Selling, general and administrative | ||||||||||||||||||||||||||
Capitalized in inventory, net | ||||||||||||||||||||||||||
| Share-based compensation expense | $ | $ | $ | $ | ||||||||||||||||||||||
11.Income Taxes
For the three and six months ended June 30, 2026, the Company recognized an income tax expense of $11.4 million and $20.9 million, respectively, compared to $0.6 million and $1.6 million, respectively, for the same periods of 2025. For the three and six months ended June 30, 2026, the Company’s effective income tax rate was 23.3 % and 22.6 %, respectively, compared to 2.9 % and 3.5 % respectively, for the same periods of 2025. The increase in the Company’s income tax expense and effective tax rate in 2026 is primarily the result of the Company’s ability to utilize unrecognized deferred tax assets in 2025. Prior to December 31, 2025, the Company maintained a full valuation allowance against its deferred tax assets. However, during the three months ended December 31, 2025, the Company released its remaining valuation allowance and recognized the full remaining benefit of the Company’s deferred tax assets. Thus, for the three and six months ended June 30, 2026, there are no available unrecognized deferred tax assets to offset income tax expense. For the three and six months ended June 30, 2026, the Company’s effective tax rate is comparable to the statutory rate. The deferred tax benefits resulting from the acquisition of Kezar will be recognized when the Company has future U.S. taxable income and will reduce income tax expense (see Note 8).
15
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q (the “Quarterly Report”) and our audited financial statements and the related notes and other financial information included in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission on February 26, 2026 (the “Form 10-K”) and with applicable Canadian securities regulatory authorities.
This Quarterly Report contains “forward-looking statements” within the meaning of U.S. federal securities laws and “forward-looking information” within the meaning of Canadian securities laws, and such statements may involve substantial risks and uncertainties. All statements, other than statements of historical facts included in this Quarterly Report, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, future expenses, business trends and other information referred to under this section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,” “anticipate,” “target,” “forecast” or the negative of these terms and similar expressions intended to identify forward-looking statements. Forward-looking statements are not historical facts and reflect our current views with respect to future events. Forward-looking statements are also based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
We discuss a number of risks, uncertainties and other factors in greater detail under the heading “Risk Factors” in Part I, Item 1A of the Form 10-K as well as in Part II, Item 1A of this Quarterly Report. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this filing. You should read this discussion completely and with the understanding that our actual future results may be materially different from what we expect. We hereby qualify our forward-looking statements by our cautionary statements. Except as required by law, we assume no obligation to update our forward-looking statements publicly, or to update the reasons that actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Overview
Background
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (“BAFF”) and a proliferation-inducing ligand (“APRIL”) for the potential treatment of autoimmune diseases.
Recent Development Progress
LUPKYNIS
Aurinia has recently initiated PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis. Belimumab is a B cell-activating factor (BAFF) inhibitor indicated for the treatment of both systemic lupus erythematosus (SLE) and lupus nephritis. Obinutuzumab is a CD20-directed cytolytic antibody indicated for the treatment of lupus nephritis. Anifrolumab is a type 1 interferon receptor antagonist indicated for the treatment of SLE. PRESERVE will investigate whether the multi-target approach of combining LUPKYNIS with these biologic agents improves outcomes in patients with lupus nephritis. Planned enrollment is approximately 150 patients across approximately 50 sites in the US. The Study’s primary endpoint is the proportion of patients achieving complete renal response (CRR) at 6 months.
Aritinercept
Aritinercept is a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Aurinia has now initiated clinical development of aritinercept in four potential indications.
16
Net Product Sales
For the three and six months ended June 30, 2026, net product sales of LUPKYNIS were $79.4 million and $153.0 million, up 19% and 21%, respectively, from $66.6 million and $126.5 million, respectively, in the same periods of 2025.
Cash Flows from Operating Activities
For the six months ended June 30, 2026, cash flows from operating activities were $85.1 million, up 87% from $45.5 million in the same period of 2025.
Cash Position
As of June 30, 2026, Aurinia had cash, cash equivalents, restricted cash and investments of $443.1 million, compared to $398.0 million at December 31, 2025. For the six months ended June 30, 2026, cash outflows from financing activities were $48.9 million, which included the repurchase of 5.0 million of the Company’s common shares for $74.9 million partially offset by proceeds from issuance of common shares for equity awards, net of tax withholding payments, of $32.7 million.
Results of Operations
Comparison of the Three and Six Months ended June 30, 2026 and 2025
The following table sets forth our results of operations for the three and six months ended June 30, 2026 and 2025 (in thousands):
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||||||||||||||
| 2026 | 2025 | Change | 2026 | 2025 | Change | |||||||||||||||||||||||||||||||||
| Revenue | ||||||||||||||||||||||||||||||||||||||
Net product sales | $ | 79,412 | $ | 66,574 | $ | 12,838 | $ | 152,975 | $ | 126,545 | $ | 26,430 | ||||||||||||||||||||||||||
License, collaboration and royalty revenue | 3,808 | 3,434 | 374 | 7,950 | 5,928 | 2,022 | ||||||||||||||||||||||||||||||||
Total revenue | 83,220 | 70,008 | 13,212 | 160,925 | 132,473 | 28,452 | ||||||||||||||||||||||||||||||||
| Operating expenses | ||||||||||||||||||||||||||||||||||||||
| Cost of revenue | 6,555 | 7,115 | (560) | 13,060 | 15,689 | (2,629) | ||||||||||||||||||||||||||||||||
| Selling, general and administrative | 23,508 | 26,018 | (2,510) | 45,537 | 46,357 | (820) | ||||||||||||||||||||||||||||||||
| Research and development | 13,050 | 7,432 | 5,618 | 20,520 | 13,175 | 7,345 | ||||||||||||||||||||||||||||||||
| Restructuring | — | 114 | (114) | — | 1,647 | (1,647) | ||||||||||||||||||||||||||||||||
| Other (income) expense, net | (6,234) | 9,246 | (15,480) | (5,955) | 13,675 | (19,630) | ||||||||||||||||||||||||||||||||
| Total operating expenses | 36,879 | 49,925 | (13,046) | 73,162 | 90,543 | (17,381) | ||||||||||||||||||||||||||||||||
| Income from operations | 46,341 | 20,083 | 26,258 | 87,763 | 41,930 | 45,833 | ||||||||||||||||||||||||||||||||
| Interest income | 3,393 | 3,190 | 203 | 6,908 | 6,759 | 149 | ||||||||||||||||||||||||||||||||
| Interest expense | (948) | (1,117) | 169 | (1,960) | (2,184) | 224 | ||||||||||||||||||||||||||||||||
| Net income before income taxes | 48,786 | 22,156 | 26,630 | 92,711 | 46,505 | 46,206 | ||||||||||||||||||||||||||||||||
| Income tax expense | 11,372 | 643 | 10,729 | 20,942 | 1,648 | 19,294 | ||||||||||||||||||||||||||||||||
| Net income | $ | 37,414 | $ | 21,513 | $ | 15,901 | $ | 71,769 | $ | 44,857 | $ | 26,912 | ||||||||||||||||||||||||||
Net Product Sales
Aurinia sells LUPKYNIS to two specialty pharmacies and a specialty distributor in the United States (the “U.S.”), and Aurinia sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), for the European and Japanese market. The two specialty pharmacies, specialty distributor and Otsuka are considered our customers for accounting purposes.
For the three and six months ended June 30, 2026, net product sales of LUPKYNIS were $79.4 million and $153.0 million, up 19% and 21%, respectively, from $66.6 million and $126.5 million, respectively, for the same periods in 2025. The increase is primarily due to an increase in the number of LUPKYNIS cartons sold to specialty pharmacies, driven by further lupus nephritis market penetration.
17
License, Collaboration and Royalty Revenue
License, collaboration and royalty revenue consists of revenue from a collaboration and licensing agreement with Otsuka to develop and commercialize oral voclosporin in voclosporin in Japan, the European Union (the “E.U.”), the United Kingdom (the “U.K.”), Switzerland, Russia, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the “Otsuka Territories”) in exchange for: (i) a $50 million upfront cash payment; (ii) regulatory and commercial milestone payments; and (iii) royalties ranging from 10% to 20% on net sales in the Otsuka Territories.
License, collaboration and royalty revenue also consists of revenue from a commercial supply agreement with Otsuka to provide manufacturing and other services, including sharing the capacity of a dedicated manufacturing facility at Lonza Ltd. (the “Monoplant”), Aurinia’s contract manufacturing partner for voclosporin.
For the three and six months ended June 30, 2026, license, collaboration, and royalty revenue was $3.8 million and $8.0 million, up 12% and 36%, respectively from $3.4 million and $5.9 million for the same periods in 2025. The increase is primarily due to manufacturing services provided to Otsuka for sharing the capacity of the Monoplant.
Cost of Revenue
Cost of revenue consists primarily of expense associated with: (i) amortization of the finance lease right-of-use asset recognized in connection with the Monoplant; (ii) manufacturing; and (iii) shipping, storage and distribution.
In December 2020, Aurinia entered into a manufacturing services agreement with Lonza Ltd. for the construction of the Monoplant. The construction of the Monoplant began in January 2021 and manufacturing of voclosporin began in late June 2023. The Monoplant is equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacturing of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand. Aurinia pays a quarterly fixed facility fee of 3.6 million Swiss Francs for the exclusive right to use the Monoplant through March 31, 2030.
For the three and six months ended June 30, 2026, cost of revenue was $6.6 million and $13.1 million, respectively, down 7% and 17%, respectively from $7.1 million and $15.7 million, respectively, for the same periods in 2025. The decrease is primarily due to a decrease in sales of LUPKYNIS inventory to Otsuka, which has a low gross margin.
For each of the three and six months ended June 30, 2026, gross margin was 92%, compared to 90% and 88%, respectively, for the same periods in 2025.
Selling, General and Administrative Expense
Selling, general and administrative (“SG&A”) expense consists of personnel and non-personnel expenses to support growing net product sales of LUPKYNIS. Personnel-related expense includes salaries, incentive pay, benefits and share-based compensation for personnel engaged in sales, finance and administrative functions. Non-personnel-related expense includes: (i) selling, patient services, pharmacovigilance, marketing, advertising, travel, sponsorships and trade shows; and (ii) other general and administrative costs, including consulting, legal, patent, insurance, accounting, information technology and facilities.
18
The following table summarizes our SG&A expense for the three and six months ended June 30, 2026 and 2025 (in thousands):
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||||||||||||||
| 2026 | 2025 | Change | 2026 | 2025 | Change | |||||||||||||||||||||||||||||||||
Personnel expense: | ||||||||||||||||||||||||||||||||||||||
Salaries, incentive pay and benefits | $ | 10,468 | $ | 10,004 | $ | 464 | $ | 23,894 | $ | 22,144 | $ | 1,750 | ||||||||||||||||||||||||||
Share-based compensation | 1,234 | 4,877 | (3,643) | 31 | 1,364 | (1,333) | ||||||||||||||||||||||||||||||||
Total personnel expense | 11,702 | 14,881 | (3,179) | 23,925 | 23,508 | 417 | ||||||||||||||||||||||||||||||||
Non-personnel expense: | ||||||||||||||||||||||||||||||||||||||
Professional fees and services | 7,268 | 5,854 | 1,414 | 12,694 | 13,142 | (448) | ||||||||||||||||||||||||||||||||
Travel, sponsorship and trade shows | 1,382 | 1,873 | (491) | 2,961 | 2,717 | 244 | ||||||||||||||||||||||||||||||||
Marketing and advertising | 535 | 848 | (313) | 862 | 1,818 | (956) | ||||||||||||||||||||||||||||||||
Other | 2,621 | 2,562 | 59 | 5,095 | 5,172 | (77) | ||||||||||||||||||||||||||||||||
Total non-personnel expense | 11,806 | 11,137 | 669 | 21,612 | 22,849 | (1,237) | ||||||||||||||||||||||||||||||||
Total SG&A expense | $ | 23,508 | $ | 26,018 | $ | (2,510) | $ | 45,537 | $ | 46,357 | $ | (820) | ||||||||||||||||||||||||||
For the three months ended June 30, 2026, the decrease in SG&A personnel expense was primarily due to: (i) a decrease in the amount of non-cash share-based compensation expense related to the departures of certain former Company officers in March 2026; and (ii) an increase in the amount of non-cash share-based compensation expense that was reversed due to forfeited, unvested equity awards during the three months ended June 30, 2026.
For the six months ended June 30, 2026, the increase in SG&A personnel expense was primarily due to a one-time expense for severance and health care benefits, related to employee departures, including certain former Company officers in March 2026 offset by: (i) a decrease to employee-related costs; and (ii) an increase in the amount of non-cash share-based compensation expense that was reversed due to forfeited, unvested equity awards during the six months ended June 30, 2026.
For the three months ended June 30, 2026, the increase in SG&A non-personnel expense was primarily due to an increase in professional fees and services, partially offset by a decrease to travel-related expenses.
For the six months ended June 30, 2026, the decrease in SG&A non-personnel expense was primarily due to lower marketing and advertising costs and professional fees and services.
We continue to expect our SG&A expense in 2026 to remain substantially consistent with 2025.
Research and Development Expense
Research and development (“R&D”) expense consists of personnel and non-personnel expenses. Personnel-related expense includes salaries, incentive pay, benefits and share-based compensation for personnel engaged in research and development functions. Non-personnel-related expense includes contract research organizations, contract manufacturing organizations and materials used for R&D activities, including development, clinical trials, clinical supply and distribution, and other professional services.
19
The following table summarizes our R&D expense for the three and six months ended June 30, 2026 and 2025 (in thousands):
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||||||||||||||
| 2026 | 2025 | Change | 2026 | 2025 | Change | |||||||||||||||||||||||||||||||||
Personnel expense: | ||||||||||||||||||||||||||||||||||||||
Salaries, incentive pay and benefits | $ | 4,412 | $ | 1,376 | $ | 3,036 | $ | 7,862 | $ | 2,684 | $ | 5,178 | ||||||||||||||||||||||||||
Share-based compensation | 1,310 | 335 | 975 | 1,421 | 428 | 993 | ||||||||||||||||||||||||||||||||
Total personnel expense | 5,722 | 1,711 | 4,011 | 9,283 | 3,112 | 6,171 | ||||||||||||||||||||||||||||||||
Non-personnel expense: | ||||||||||||||||||||||||||||||||||||||
Clinical supply and distribution | 4,455 | 3,145 | 1,310 | 7,054 | 5,010 | 2,044 | ||||||||||||||||||||||||||||||||
Contract research organizations and developmental expenses | 2,072 | 2,522 | (450) | 3,262 | 4,871 | (1,609) | ||||||||||||||||||||||||||||||||
Other | 801 | 54 | 747 | 921 | 182 | 739 | ||||||||||||||||||||||||||||||||
Total non-personnel expense | 7,328 | 5,721 | 1,607 | 11,237 | 10,063 | 1,174 | ||||||||||||||||||||||||||||||||
Total R&D expense | $ | 13,050 | $ | 7,432 | $ | 5,618 | $ | 20,520 | $ | 13,175 | $ | 7,345 | ||||||||||||||||||||||||||
For the three and six months ended June 30, 2026, the increase in R&D personnel-expense was primarily due to an increase in employee-related costs to support development activities.
For the three and six months ended June 30, 2026, the increase in R&D non-personnel expense was primarily as a result of an increase in clinical supply and distribution, partially offset by lower contract research organization and developmental expenses due to timing and support of our development activities.
We expect our R&D expense to increase as we progress our development activities.
Other (Income) Expense, Net
For the three and six months ended June 30, 2026, other (income) expense, net was $(6.2) million and $(6.0) million, respectively, compared to $9.2 million and $13.7 million, respectively, for the same periods in 2025. The change is primarily due to: (i) favorable changes in the foreign exchange remeasurement of the finance lease liability recognized in connection with the Monoplant, which is denominated in Swiss Francs; (ii) reduction in other liabilities from the one-time payment to fully settle all future obligations under one arrangement; and (iii) reduction of an accrual related to shareholder matters.
Income Tax Expense
For the three and six months ended June 30, 2026, income tax expense was $11.4 million and $20.9 million, respectively, compared to $0.6 million and $1.6 million, respectively, for the same periods in 2025. The increase in the Company’s income tax expense in 2026 over the same periods in 2025 is primarily the result of the Company’s ability to utilize unrecognized deferred tax assets in 2025 to reduce the income tax expense. These unrecognized deferred tax assets were recognized in the three months ended December 31, 2025 and were not available to offset income tax expense for the three and six months ended June 30, 2026.
Liquidity and Capital Resources
As of June 30, 2026, Aurinia had cash, cash equivalents, restricted cash and investments of $443.1 million, compared to $398.0 million at December 31, 2025. For the six months ended June 30, 2026, cash flows from operating activities were $85.1 million, up 87% from $45.5 million in the same period of 2025. For the six months ended June 30, 2026, cash outflows from financing activities were $48.9 million, which included the repurchase of 5.0 million of the Company’s common shares for $74.9 million partially offset by proceeds from issuance of common shares for equity awards, net of tax withholding payments, of $32.7 million.
Based on our current operating plans and projections, the Company expects to fund future operations with existing cash or cash flows from operating activities.
The amount and timing of additional future funding needs, if any, will depend on many factors, including the success of our commercialization efforts for LUPKYNIS and our ability to control expenses. If necessary, we intend to raise additional capital through equity or debt financings. We can provide no assurance that additional financing will be available to us on favorable terms, or at all.
20
Critical Accounting Estimates
There have been no material changes to our critical accounting policies and significant judgments and estimates as described in our Annual Report on Form 10-K for the year ended December 31, 2025.
Off‑Balance Sheet Arrangements
During the periods presented, we did not have, nor do we currently have, any off‑balance sheet arrangements as such term is defined in Item 303(a)(4)(ii) of Regulation S-K under the Securities Act.
Contractual Obligations
There have been no material changes outside the ordinary course of business to our contractual obligations and commitments as described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2025.
Item 3. Quantitative and Qualitative Disclosures About Market Risks.
There have been no material changes to our quantitative and qualitative disclosures about market risks as described in our Annual Report on Form 10-K for the year ended December 31, 2025.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of June 30, 2026, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
21
PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
There are no material developments to report in respect of the legal proceedings described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
Item 1A. Risk Factors.
Under Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025, we identified important factors that could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Quarterly Report. There has been no material change in our risk factors subsequent to the filing of our prior reports referenced above. However, the risks described in our reports are not the only risks we face. Additional risks and uncertainties that we currently deem to be immaterial or not currently known to us, as well as other risks reported from time to time in our reports to the SEC, also could cause our actual results to differ materially from our anticipated results or other expectations.
Item 2. Unregistered Purchases or Sales of Equity Securities and Use of Proceeds.
In February 2024, the Board approved a share repurchase program of up to $150 million of the Company’s common shares (“Share Repurchase Plan”). In July 2025, the Company announced that the Board had approved an increase to the previously announced Share Repurchase Plan of an additional $150 million of the Company’s common shares. Purchases under the Share Repurchase Plan, which to date have totaled 23.3 million of its common shares for $213.4 million, began on February 21, 2024. The timing and amount of future repurchase transactions will be determined by the Company based on its evaluation of market conditions, share price, legal requirements, including applicable blackout period restrictions, and other factors. Under Alberta law, the repurchased common shares are cancelled and not reissued.
The following table summarizes the common share activity of our repurchased shares under the Share Repurchase Plan for the three months ended June 30, 2026.
Period | Total number of shares purchased | Average price paid per share in $ | Total number of shares purchased as part of publicly announced program | Approximate dollar value of shares that may yet be purchased under program (in thousands)(1) | ||||||||||||||||||||||
| 4/1/2026-4/30/2026 | 1,977,966 | $15.84 | 1,977,966 | $93,978 | ||||||||||||||||||||||
| 5/1/2026-5/31/2026 | 473,651 | $15.50 | 473,651 | $86,634 | ||||||||||||||||||||||
| 6/1/2026-6/30/2026 | — | — | — | $86,634 | ||||||||||||||||||||||
Total | 2,451,617 | 2,451,617 | ||||||||||||||||||||||||
(1)Does not include broker commissions.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
None.
None.
22
Item 6. Exhibits.
The following exhibits are filed as part of this report:
| Exhibit Number | Description | |||||||
| 3.1 | Articles of Amalgamation, as amended, as currently in effect (filed as Exhibit 3.1 to the Company's Annual Report on Form 10-K with the SEC on February 24, 2021 and incorporated herein by reference) | |||||||
| 3.2 | Amended and Restated By-Law No. 2 amended as of May 15, 2025 (filed as Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the SEC on May 15, 2025 and incorporated herein by reference) | |||||||
| 31.1* | Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |||||||
| 31.2* | Certification of Principal Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |||||||
| 32.1** | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||||||
| 32.2** | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||||||
| 101.INS* | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | |||||||
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |||||||
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||||||
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |||||||
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |||||||
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | |||||||
| * | Filed herewith. | |||||||
| ** | Furnished herewith. Exhibits 32.1 and 32.2 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing. | |||||||
23
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| AURINIA PHARMACEUTICALS INC. | ||||||||
| August 5, 2026 | By: | /s/ Kevin Tang | ||||||
Kevin Tang | ||||||||
| Chief Executive Officer and Chair of the Board (Principal Executive Officer) | ||||||||
| August 5, 2026 | By: | /s/ Michael Hearne | ||||||
Michael Hearne | ||||||||
| Chief Financial Officer (Principal Financial and Accounting Officer) | ||||||||
24